ArticleVirchows Archiv : an international journal of pathology2026
Histology-defined activated cancer-associated fibroblasts are associated with poor survival in diffuse-type gastric adenocarcinoma.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Activated cancer-associated fibroblasts (aCAFs), characterized by distinct histological features including fibroblast proliferation and extensive desmoplasia, play a key role in tumor progression induced by cancer cell infiltration and may serve as important predictive and prognostic factors in gastric cancer (GC). This study investigated the relationship between aCAFs and clinicopathologic factors and their impact on survival outcomes in 691 GC patients across two independent cohorts. aCAFs were identified based on histological features on H&E-stained slides, and clinicopathological parameters, survival outcomes, immune cell composition, and transcriptomic features were comprehensively evaluated. Publicly available transcriptomic datasets were also analyzed for translational insights. aCAFs were significantly associated with advanced T and N stages, vascular/lymphatic/perineural invasion, and necrosis. Higher histological grade tended to correlate with increased aCAF frequency (P = 0.061). Notably, aCAFs were less frequently observed in diffuse-type GC according to Lauren classification and in poorly cohesive carcinoma according to WHO classification compared to other subtypes (all P < 0.05). The presence of aCAFs was significantly associated with poor survival in diffuse-subtype GC and WHO-defined poorly cohesive carcinoma on univariate and multivariate analyses (all P < 0.05). aCAFs correlated with immune dysfunction but were not related to CD4 + and CD8 + T cell counts. Incorporating aCAF status modestly but consistently improved survival prediction in machine learning-based prognostic models. Histologically identifiable aCAFs on routine H&E slides represent a clinically accessible prognostic biomarker in diffuse-subtype GC, highlighting the importance of stromal morphology in risk stratification and providing a translational framework for future therapeutic studies targeting the tumor microenvironment.
Indexed as
Identifiers
42089921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.